109 related articles for article (PubMed ID: 21447973)
1. Correlation between Heterogeneous Expression of Sialyltransferases and MUC16 in Ovarian Tumor Tissues.
Bouanene H; Sahrawi W; Mokni M; Fatma LB; Bouriga A; Limen HB; Khairi H; Ahmed SB; Miled A
Onkologie; 2011; 34(4):165-9. PubMed ID: 21447973
[TBL] [Abstract][Full Text] [Related]
2. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
White NM; Mathews M; Yousef GM; Prizada A; Fontaine D; Ghatage P; Popadiuk C; Dawson L; Doré JJ
Cancer Biomark; 2009; 5(6):279-87. PubMed ID: 20037204
[TBL] [Abstract][Full Text] [Related]
3. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
4. Altered mRNA expressions of sialyltransferases in ovarian cancers.
Wang PH; Lee WL; Juang CM; Yang YH; Lo WH; Lai CR; Hsieh SL; Yuan CC
Gynecol Oncol; 2005 Dec; 99(3):631-9. PubMed ID: 16112178
[TBL] [Abstract][Full Text] [Related]
5. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
[TBL] [Abstract][Full Text] [Related]
6. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
[TBL] [Abstract][Full Text] [Related]
8. [The characteristics of CA125/MUC16].
Hiraike O; Yano T; Taketani Y
Nihon Rinsho; 2010 Jul; 68 Suppl 7():681-4. PubMed ID: 20960850
[No Abstract] [Full Text] [Related]
9. Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer.
McLemore MR; Aouizerat B
Biol Res Nurs; 2005 Apr; 6(4):262-7. PubMed ID: 15788735
[TBL] [Abstract][Full Text] [Related]
10. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
11. A study of ovarian cancer biomarker amplification using ultrasound for early stage detection.
Peng D; Xu T; Mason TJ; Wu W
Ultrasonics; 2014 Feb; 54(2):451-4. PubMed ID: 23823706
[TBL] [Abstract][Full Text] [Related]
12. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract][Full Text] [Related]
13. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Boivin M; Lane D; Piché A; Rancourt C
Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
[TBL] [Abstract][Full Text] [Related]
14. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
15. B7-H4 expression in Brenner tumours, a descriptive and comparative study.
Yee EU; Zaino RJ; Torkko KC; Shroyer KR
Histopathology; 2010 Apr; 56(5):652-4. PubMed ID: 20459576
[No Abstract] [Full Text] [Related]
16. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
17. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
Wang Y; Cheon DJ; Lu Z; Cunningham SL; Chen CM; Luo RZ; Xing D; Orsulic S; Bast RC; Behringer RR
Differentiation; 2008 Dec; 76(10):1081-92. PubMed ID: 18637025
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
19. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
Ricardo S; Marcos-Silva L; Pereira D; Pinto R; Almeida R; Söderberg O; Mandel U; Clausen H; Felix A; Lunet N; David L
Mol Oncol; 2015 Feb; 9(2):503-12. PubMed ID: 25454345
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]